• Explore /
  • Poster
  • / SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of <em>BRAF</em> V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC).

SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC).

Abstract Poster

Authors

null

Scott Kopetz

MD Anderson Cancer Center, Houston, TX

Scott Kopetz , Tanios S. Bekaii-Saab , Takayuki Yoshino , Chin-Hee Chung , Xiaosong Zhang , Josep Tabernero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT05217446

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS3634)

DOI

10.1200/JCO.2022.40.16_suppl.TPS3634

Abstract #

TPS3634

Poster Bd #

425a

Abstract Disclosures

Similar Posters

First Author: Scott Kopetz

First Author: Yuki Matsubara

First Author: Chetan Vakkalagadda

First Author: Daisuke Kotani